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Abstract 
Objective. To explore the determinants of incident hypertension, and especially the impact of 
baseline blood pressure category, in a representative Swedish population during 10 years 
follow-up. 
Design and method. A population based cohort study with sex ratio 1:1 and mean age 47. 
Blood pressures were measured and categorized according to ESH guidelines with optimal 
blood pressure <120/80 mmHg, normal 120-129/80-84 mmHg, high normal 130-139/85-89 
mmHg, and unstable ≥140 systolic and/or ≥90 mmHg diastolic at one or two visits. 
Hypertension was defined as ongoing treatment or readings of ≥140 and/or ≥ 90 mmHg at 
three consecutive visits. Subjects with hypertension at baseline were excluded. Data were 
analyzed with multiple binary logistics regression. 
Results. At baseline, blood pressure was optimal in 633 subjects (56.1%), normal in 292 
(25.9%), high normal in 141 (12.5 %) and unstable in 63 (5.6%). Within the optimal blood 
pressure group 18 (2.8%) converted to hypertension during follow up. Corresponding 
numbers for subjects with normal, high normal and unstable blood pressure were 58 (19.9%), 
56 (39.7%) and 47 (74.6%) respectively. Normal, high normal and unstable baseline blood 
pressure were all associated with an increased risk of development to manifest hypertension 
compared to optimal blood pressure, with odds ratios (OR) and 95% CI of 5.4 (2.9-9.9), 12.5 
(6.3-24.8) and 87.5 (33.1-231.4), respectively, independent of age and other main 
cardiovascular risk factors. The progression to hypertension was also independently predicted 
by age, BMI and family history of hypertension, with OR 1.03 (1.00-1.05), 1.12 (1.05-1.19) 
and 2.59 (1.59-4.23), respectively. 
Conclusions. Subjects with high normal or unstable blood pressure should be identified in 
clinical practice and evaluated for global risk accounting for family history of hypertension. 
Thereupon personalized advice on lifestyle modification should be given, as early prevention 
of cardiovascular disease. 
Keywords: Incident hypertension, high normal blood pressure, prehypertension, cohort, 
population survey. 
  
Populärvetenskaplig sammanfattning på svenska 
Högt blodtryck, eller hypertoni, är vanligt förekommande och ökar risken att drabbas av hjärt- 
och kärlsjukdomar så som t.ex. hjärtinfarkt och stroke. Orsakerna till högt blodtryck är inte 
helt klarlagda men forskning har visat att det hänger nära samman med övervikt och typ 2 
diabetes samt även med livshållning - brist på motion, frukt- och grönsaksfattig kost och högt 
saltintag samt att det i viss mån också är ärftligt. Även om högt blodtryck blir betydligt 
vanligare med åldern finns anledning att misstänka att utvecklingen som leder dit tar sin 
början redan i relativt unga år. 
I denna studie har vi försökt att ytterligare kartlägga orsakerna bakom högt blodtryck genom 
att i 10 år följa en stor grupp individer i åldrarna 30-74 år från Vara och Skövde kommun. Vid 
studiens början undersöktes deltagarna, lämnade blodprover samt information om sitt 
hälsotillstånd, psykiska mående och sina levnadsvanor. Deltagarnas blodtryck mättes också 
och delades in i fem kategorier, närmare bestämt optimalt (<120/80 mmHg), normalt (120-
134/80-84 mmHg), högt normalt (135-139/85-89 mmHg), högt blodtryck (≥140/90 mmHg) 
samt instabilt blodtryck (blodtryck som växlade mellan högt och normalt mellan olika 
mättillfällen). De som hade högt blodtryck redan vid studiens start, eller medicinerade mot 
detta, uteslöts. Efter 10 år genomgick deltagarna samma procedurer igen. Vi noterade vilka 
som drabbats av högt blodtryck och jämförde detta med övriga uppgifter vi hade om 
individerna. Vi såg att bland de som haft högt normalt eller instabilt blodtryck från början var 
det betydligt fler som utvecklat hypertoni än i gruppen med ursprungligt optimalt tryck. Detta 
gällde även oberoende ålder inom grupperna och andra faktorer som anses kunna påverka 
blodtrycket. Äldre individer, överviktiga och personer med släktingar (föräldrar eller syskon) 
med högt blodtryck var också överrepresenterade i gruppen som utvecklat högt blodtryck. 
Även rökning sågs ha ett samband med höjning av blodtrycket. 
Vi har genom denna studie med stor statistisk säkerhet fastslagit att personer med ett 
blodtryck som ligger högt i det normala intervallet löper en markant ökad risk att på sikt 
drabbas av högt blodtryck jämfört med de som har optimalt blodtryck. Ärftlighet för 
hypertoni är också av stor betydelse för denna risk. I framtiden kan dessa resultat vara till 
hjälp i utvecklingen av bedömningsmallar för läkare på vårdcentral, tänkta som stöd i vården 
av patienter som ännu inte har högt blodtryck men som riskerar att få det. Genom att sätta in 
lämplig insatser, så som livsstilsförändringar i tid han man chans att bromsa utveckling mot 
högt blodtryck och på så vis minska risken för alvarliga, potentiellt dödliga följdsjukdomar i 
hjärta och kärl. 
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1.  Background 
 
Introduction 
Hypertension is a common condition, strongly associated with cardiovascular mortality and 
morbidity [1, 2]. In fact, since 2010 it has been established also as the leading cause behind 
the world’s global burden of disease. The mechanisms behind essential hypertension are 
complex and based on interactions between multiple biological and behavioral factors [3]. 
Age, insulin resistance and overweight are known to be strong predictors [4], and so is genetic 
predisposition [3]. Nevertheless lifestyle aspects such as physical inactivity, smoking, low 
intake of fruits and vegetables and high alcohol consumption have also been associated with 
the progression of hypertension [5-8]. The prevalence of hypertension increases with age [9], 
but earlier longitudinal studies also show that blood pressure levels late in life can be traced 
back to levels earlier in life, even in childhood [10]. In a similar fashion it has been shown 
that subjects with high blood pressure within the normal range, with a high normal blood 
pressure, are at increased risk of developing hypertension compared to subjects of normal or 
optimal blood pressure [11]. The connection between hypertension and cardiovascular disease 
(CVD) is well established, but increased prevalence of CVD has actually been seen in relation 
to blood pressure levels across the entire blood pressure distribution, also within the normal 
range [12]. These observations support the recommendation to monitor blood pressure in non-
hypertensive individuals regularly [13], as well as indicate an important field of study. Over 
recent decades awareness concerning hypertension and its preliminary stages, determinants 
and risks, has increased [14]. Nevertheless medical, economic and human costs related to 
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hypertension are still enormous [15], forcefully justifying further research on the determinants 
of hypertension and subsequent trials on new potential preventive strategies. 
 
Definition of hypertension 
Guidelines for the management of hypertension have existed for over 30 years even if the 
definition of the condition has altered [13, 16, 17]. In 1993 however, the limit for diagnosis of 
hypertension was lowered to 140/90 mmHg [17] and in late 1990s two new blood pressure 
categories were introduced by the Word Health Organization and the International Society of 
Hypertension [18], namely, optimal blood pressure and high normal blood pressure. At the 
same time hypertension was further categorized into grade I, grade II, and grade III. These 
categories, as well as the hypertension limit, have essentially remained unchanged to this date 
and were once again presented among the joint guidelines of the European Society of 
Hypertension and the European Society of Cardiology (ESH/ESC) in 2013, see Table 1.1. 
 
Table 1.1. Blood pressure categories according to ESH/ESC guidelines 2013. 
Category Systolic (mmHg)   Diastolic (mmHg) 
Optimal <120 and <80 
Normal 120-129 and/or 80-84 
High normal 130-139 and/or 85-89 
Grade 1 hypertension 140-159 and/or 90-99 
Grade 2 hypertension 160-179 and/or 100-109 
Grade 3 hypertension ≥180 and/or ≥110 
When a subject’s systolic and diastolic blood pressures fall into different categories, the higher 
category should apply. 
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Development of hypertension 
In 5-10 % of hypertensive subjects there is an identifiable underlying disease causing the 
blood pressure elevation [19], such as primary aldosteronism, renal artery stenosis or 
obstructive sleep apnea, the condition therefore referred to as secondary hypertension. The 
vast majority of hypertension cases though, is attributed to primary or essential hypertension, 
the cause of which is complex, and subject of research. 
The association between overweight and hypertension is generally acknowledged and an 
almost linear relation has been established between BMI and blood pressure [20]. Some 
studies suggests that weight gain may account for 64-78 % of human essential hypertension 
[21], making it an invaluable risk factor to consider, especially since the epidemic of obesity 
is steadily growing nearly all across the world [20]. Closely related to overweight is the so 
called metabolic syndrome, besides overweight, and especially of abdominal type, including 
high blood pressure, atherogenic dyslipidemia (i.a. high serum levels of LDL and triglycerides 
and low serum levels of HDL), insulin resistance with glucose intolerance, as well as 
proinflammatory and prothrombotic states [20]. A further development of the impaired 
glucose metabolism and insulin resistance in the metabolic syndrome, could lead to frank type 
2 diabetes [20]. Even if it in recent years has been subject of some debate, the clinical 
relevance of the metabolic syndrome concept is usually acknowledged [13].The abnormalities 
included in the syndrome are generally believed not only to correlate, but also to potentiate 
each other [4], leading to cardiovascular risk higher than the sum of risks associated with the 
individual factors. Several pathophysiologic mechanism combine to create these interactions, 
some of them yet not fully understood and [20]. There are hemodynamic changes occurring in 
relation to obesity and metabolic syndrome believed to start out from endothelial dysfunction, 
impaired vasodilation and microvascular recruitment (the ability of small vessel beds to react 
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with vasodilation on increased flow in large vascular beds). These effects are at least in part 
mediated by insulin, through its attenuating effect on endothelial release of nitric oxide, a 
potent vasodilator, and also promoting vascular hypertrophy based on its progrowth effects as 
a hormone. Later, such small vessel effects may translate into stiffness in large arterial 
conduits, with both hypertensive and arteriosclerotic consequences. Visceral adipose tissue 
hormones such as Leptin has also gained a lot of attention in recent years [20], believed to be 
one of the most important signals in regulation of energy homeostasis. Some earlier studies 
have found plasma norepinephrine levels to be elevated in obese persons, a possible 
explanation being the norepinephrine and epinephrine releasing effect of leptin trough 
stimulus of ventral hypothalamus [20]. Elevated adrenergic tone contributes to endothelial 
dysfunction [20] as well as decreased arterial responsiveness to vasodilation, with overall 
increased vascular tone and hypertension as a consequence. The enhanced adrenergic tone 
also causes activation of the renin-angiotensin-aldosterone system (RAAS), increasing renal 
sodium retention and peripheral resistance, thereby contributing to hypertension. Elevated 
levels of the angiotensin II hormone is also believed to affect insulin signaling pathways [20], 
although precise mechanism has not been clearly defined. Several trials tough [20], have 
shown fewer cases of new-onset diabetes when angiotensin receptor blockers or angiotensin-
converting enzyme inhibitors are used in hypertensive patients. High circulating insulin levels 
in turn, also exert sodium retentive effects. It is well established that inflammation is an 
important mechanism behind the development of atherosclerosis [22], but in recent years it 
has also been posed that oxidative stress, and the consequent inflammatory response, play an 
important role in association with obesity and is an underlying factor also in insulin resistance 
and the metabolic syndrome as a whole [22]. 
It is undisputed that lifestyle aspects also are effecting the risk of developing hypertension 
[13]. The protective effect of physical activity regarding both hypertension and CVD is well 
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established [5], acting directly on blood pressure but also indirect trough weight reduction and 
improved insulin sensitivity [23]. Moderate alcohol consumption has in many population 
based studies shown a protective effect in relation to multiple cardiovascular outcomes, 
including cardiovascular death [24]. These findings however, are according to some, rather 
the result of underestimated bidirectional confounding than a causality [6]. Extensive alcohol 
consumption, in any case, raises blood pressure [25] and in the World Health Organization 
Global Burden of Disease Comparative Risk Analysis study from 2000, 16 % of all 
hypertension should be attributed to alcohol consumption [6]. Regarding the relationship 
between hypertension and smoking results differ [7]. The lower blood pressures seen in 
smokers in some studies, compared to non-smokers could at least in part be attributed to 
residual confounding with body weight whereas smokers are generally thinner than non-
smokers [26]. Longitudinal studies, however, shows that long-term smoking in fact increases 
blood pressure and constitutes a risk factor for hypertension [7]. High sodium intake has a 
well-documented blood pressure elevating effect, and a high habitual salt intake is one of the 
quantitatively important, preventable factors causing unfavorable population-wide blood 
pressure patterns [27]. The hypertensive effect of liquorice is well known [28], but the size of 
this effect differs greatly between individuals, which at least partially can be attributed to a 
certain genetic mutation. 
Psychological stress has been suggested as an underlying cause of hypertension, and has also 
been implicated as a part in the pathogenesis of the metabolic syndrome [29]. The principal 
hypothesis is that chronic stress-induced activation of the two interacting effector systems, the 
sympathetic nervous system and the hypothalamic–pituitary–adrenal axis, and the consequent 
release of catecholamines and cortisol, could lead to cardiovascular adjustments and an 
increased risk of hypertension. This theory has found support both in animal and human 
studies [29]. It has furthermore been posed [29] that psychosocial factors interplay with 
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certain genetic variants, making some individuals more vulnerable to these effects than others. 
Behavior-based approaches, such as meditation, muscle relaxation and yoga have shown to 
have some, although moderate, decreasing effect on blood pressure [30]. 
Hypertension has since long been recognized to cluster within families [13]. Heritability has 
been estimated to vary between 35% and 50% in different studies [13], and a positive family 
history of hypertension has been suggested to double the risk, independently of overweight 
[31]. The genetic component of essential hypertension is not arising from a single gene, but 
rather from a wide range of different combinations [13]. Several genome-wide association 
studies and their meta-analyses have identified a total 16 genetic locus associated with blood 
pressure regulation, and 29 genetic variants correlated with hypertension [32]. 
 
Recommended blood pressure measurements 
To reduce misclassification of hypertension, blood pressure should be measured in a 
standardized fashion [33]. Intra-individual variation in blood pressure, as well as the 
somewhat disputed “white coat effect” [13] is known to cause over estimation of 
hypertension, and accordingly repeated readings are recommended [34]. The recent ESH/ESC 
guidelines further recommend: 
 To allow the patient to sit for 3-5 minutes before beginning blood pressure measurements 
 To take at least two blood pressure measurements, spaced 1-2 min apart, and if deemed 
appropriate, take the mean of the two blood pressure readings 
 To use a standard bladder (12-13 cm wide and 35 cm long), but have a larger and smaller 
bladder available for large arms (circumference >32 cm) and thin arms (circumference 17-
22cm), respectively (alternatively use a self-adjusting bladder) 
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 To have the cuff at heart level, whatever the position of the patient 
 
Furthermore, a quiet, comfortable location for the patient in a room of normal room 
temperature, is optimal. Ideally the patient should not recently have eaten, smoked, exercised, 
or taken caffeine [33]. When using the auscultatory method, the phase I (appearance) and V 
(disappearance) of the Korotkoff sounds should be used to identify systolic and diastolic 
blood pressure, respectively. A semiautomatic oscillometric devise may equivalently be used 
instead [13]. Provided that the arm is supported at heart level, measurements from sitting and 
supine position are considered comparable [33]. The examiner should be well trained in the 
techniques of blood pressure measurement and use accurate and properly maintained devices, 
checked periodically through calibration [13]. Out-of-office blood pressures, at home or by 
24-hour ambulatory measurements, is an option when for example episodic hypertension is 
suspected. 
 
Prevalence 
Hypertension is equally common in men and women and is increasing with age [35]. The 
prevalence appear to differ across the world, tough there are limited comparable data 
available. Reported figures differ between European countries [13] as well as across the 
world. The European average in hypertension prevalence has been estimated to 44 % as 
compared to 28 % in North America [36], the cause of the extensive difference not being fully 
understood. Since 1980 though, there has been a slight decrease in average blood pressures in 
the western world [14]. In low-income countries, however, an inverse trend is seen, with 
evaluations of recent publications [37] showing a 30 % prevalence of hypertension in the 
adult (30–60 years of age) population in sub-Saharan Africa, poorly acknowledged and 
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controlled. According to the Swedish Agency for Health Technology Assessment and 
Assessment of Social Services (SBU) [35] 1.8 million, or 27 %, of the Swedish adult 
population (age 20+) are subjects to hypertension, and by the age of 65 the prevalence has 
raised to more than 50 %. In an earlier study on the Vara-Skövde cohort (age range 30-74), 
the hypertension prevalence was found to be 20 % [38]. Among Swedish subjects with 
hypertension 60 % have mild hypertension (grade I), 30 % moderate (grade II) while 10 % are 
suffering from severe hypertension (grade III). Earlier studies [39, 40] estimates the number 
of subjects of high normal blood pressure to about 20 % in the grown up population. 
 
Cardiovascular risk and prevention  
There are risk grading tools developed to correctly identify patients in need of treatment. The 
most commonly used in Northern Europe today is SCORE (Systematic Coronary Risk 
Evaluation) [41]. SCORE calculates the 10-year risk of cardiovascular death using systolic 
blood pressure combined with sex, age, serum cholesterol and smoking. In presence of 
diabetes, the calculated cardiovascular risk is believed to be tripled in men, and fivefold 
higher in women. Estimated risk at 5 % or higher, it is considered high and pharmacological 
treatment is generally recommended [42]. 
It’s an undisputed fact that treatment reduces mortality in subjects of moderate and severe 
hypertension, while treatment of mild hypertension, treatment goals and approach to certain 
subgroups have been subjects to never-ending reconsiderations [13]. Previous ESH 
guidelines, from 2007, in similarity with many other expert guidelines, set blood pressure 
treatment goals to <140/90 mmHg for the general population, and <130/80 mmHg for patients 
with diabetes [42]. ESH:s most recent guidelines, tough, states that systolic blood pressure 
under 140 mmHg (in the elderly between 140 and 150 mmHg) and diastolic blood pressure 
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under 90 mmHg is always recommended, except in patients with diabetes in whom diastolic 
blood pressure should not exceed 85 mmHg [13]. This was the result of a careful review of 
available evidence. In stage I and II of hypertension furthermore, it is advisable to try life 
style modification before the initiation of drug treatment, while in stage III recommendations 
are to start pharmacological treatment immediately, together with lifestyle changes, in order 
to effectively reduce cardiovascular risk [13]. 
Even though improvements have been made [14], hypertension is still largely undertreated, 
not only in low income countries but also, still, in the western world and according to 
observations, especially in Europe [37]. Earlier European studies have led to the formulation 
of “the rule of halves” [43] stating that among all subjects with hypertension, only half of 
them are aware of their condition, and among those aware, half are treated and among those 
treated only half are reaching the treatment goals. Earlier analysis of the Vara-Skövde cohort 
indicated 64 % of hypertensive subjects being aware, and among those about half were well 
controlled [38], indicating progress but still plenty of room for improvement. 
 
Treatment: pharmacological and non-pharmacological 
Lifestyle modification is considered a cornerstone in prevention and treatment of hypertension 
[13]. Actually, lifestyle changes have proven to potentially reduce blood pressure equivalently 
to drug mono therapy, with its major drawback being low level of adherence over time. Most 
recent ESH guidelines [13] states the following as lifestyle measures able to lower blood 
pressure: weight reduction, regular physical exercise, salt restriction, moderation of alcohol 
consumption and high consumption of fruits and vegetables. Regarding pharmacological 
treatment international guidelines conclude [13] that the main benefits of antihypertensive 
treatment are due to the lowering of blood pressure per se and is largely independent of the 
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drugs employed. Large meta-analyses show no clinically relevant difference between the 
common classes of blood pressure lowering medications, with exceptions made for certain 
patient’s subgroups, such as diabetics and subjects of heart failure [13]. 
 
High normal blood pressure 
 
“Arterial pressure is a quantity and its adverse effects are related numerically to it. The 
dividing line (between normal blood pressure and hypertension) is nothing more than an 
artifact.” 
 
Sir George Pickering, 1968 [44] 
 
As is obvious from the above quote the thought of the possible clinical relevance of blood 
pressures below the level of defined hypertension have crossed the minds of researchers for a 
long time. Actually already in 1939 Robinson and Brucer [39] defined blood pressures in the 
range of 120–139/80–89 mmHg as prehypertensive, after having observed that many 
hypertensives originated from this part of the blood pressure range and that these individuals 
had about double the mortality of people with blood pressures less than 120/80 mmHg. This 
last observation seems to have remained true in subsequent studies even if the figures vary. 
Results from a recent meta-analysis [44] of data from 61 prospective studies demonstrate that 
blood pressure in the general population down to a level of 115/75 mmHg, is related to 
elevated incidence of ischemic heart disease mortality, stroke mortality, and mortality from 
other vascular causes. Referring to such findings, some experts claim that the term 
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prehypertensive should more properly be applied to blood pressures of 120–139/80–89 mm 
Hg. This interval is then usually further divided into stage 1 prehypertension 120-129/80-84, 
and stage 2 prehypertension, 130–139/85–89 mm Hg, equivalent to the ESH-definitions of 
strict normal and high normal blood pressure respectively. 
An earlier Swedish population-based survey found the prevalence of high normal blood 
pressure to be 27% in the study population consisting of young middle-aged men in southern 
Sweden [40]. Previous analyses of the Vara-Skövde cohort showed 12 % high normotensives 
at baseline [45], quite similar to figures reported from North America of 14 % in the grown-
up population [39]. As mentioned earlier, subjects of high normal blood pressure, in addition 
to running an elevated CVD risk, are more likely to develop overt hypertension [11]. Meta-
analysis of longitudinal studies across the entire life span has shown that even elevated 
childhood blood pressure is associated with high blood pressure later in life [10], suggesting 
that the progress towards hypertension starts very early.  
Estimates of the exact conversion rate vary. Among the above-mentioned middle-aged men in 
southern Sweden, 24 % converted to hypertension within 3 years and 46 % of the original 
number of subjects with high normal blood pressure had converted after 6 years [40]. In the 
American TROPHY study, 52 % converted within 4 years [39].  Framingham heart study, the 
famous cohort started in 1948, concluded that after 26 years as many as 75 % of the subjects 
with high normal blood pressure at baseline had converted to hypertension [11]. To conclude, 
despite the fact that unanimous data is lacking, it is clear that subjects with high normal blood 
pressure are at a significantly elevated risk of developing hypertension, and it seems that at 
least every second of them within 5-10 years do. 
It has also been shown [39] that subjects of high normal blood pressure, compared to those of 
optimal blood pressure, are more likely to be overweight, insulin resistant, exhibit 
dyslipidemia and show high levels of inflammatory cytokines and to display endothelial 
12 
 
dysfunction. Most patients of high normal blood pressure have at least one other major 
cardiovascular risk factor [39]. Meta-analysis of several cohort studies estimates the risk of 
clinical cardiovascular disease in subjects of high normal blood pressure to be doubled 
compared to subjects with optimal blood pressure, and this is independent of the progression 
to hypertension [39].  
Being a subject of ongoing trials and discussion, high normal blood pressure should according 
to international guidelines [13, 46] be treated solely with life style modification, since benefits 
of pharmacological treatment have failed to clearly show. What has been seen is that a few 
years’ administration of antihypertensive agents to individuals with high normal blood 
pressure can delay transition to hypertension [47], but how far this benefit goes, whether it 
can also delay cardiovascular events and be cost effective, remains to be proven [13]. The 
benefits of lifestyle intervention on subjects of high normal blood pressure have, in the 
relatively small extent to which it is investigated, shown efficacious for preventing or 
delaying hypertension and for reducing cardiovascular morbidity and mortality in affected 
subjects [39, 48]. 
Essential hypertension acts as both cause and effect in a complex etiologic machinery, starting 
from cardiovascular alterations [44], in many cases probably initiated already at young age 
[40]. Subjects of high normal blood pressure, especially in younger population strata, 
constitute a highly interesting group, still poorly studied, potentially holding a large part of 
the key to the public health issue of hypertension. In order to take the next significant step in 
better prevention of hypertension and cardiovascular disease, we need to fill out the gap by 
more detailed data on the prevalence of high normal blood pressure, characteristics of the 
affected group and its longitudinal outcomes, which is what this study is addressing. 
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2. Aim 
General aim 
To investigate the development of hypertension in a relatively young, representative Swedish 
population over a decade, as a part in better understanding the determinants of hypertension. 
The overall aim is to provide necessary knowledge for future development of better 
preventive strategies that can help reducing cardiovascular morbidity and mortality. 
Specific aim 
- Determine the proportion of subjects with optimal, normal, high normal and unstable 
baseline blood pressure that has converted to hypertension, respectively, during the 
follow-up time. 
- Investigate which factors are associated with conversion to hypertension and which are 
associated with an overall progression in blood pressure category, with special focus on 
determining the impact of baseline blood pressure. 
 
3. Methods 
Subjects 
In 2002-2005 the baseline survey was conducted in the municipalities of Vara and Skövde, 
resembling the starting point of “the Vara-Skövde cohort”. From the population census 
register of the two municipalities, a computer-generated random sample was drawn in the age 
interval of 30-74 years, stratified by gender and five-year age groups. A three-fold over-
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sampling was performed in subjects 30-50 years of age, as compared to subject over 50 years 
in order to obtain the relatively young population required to meet the aims of the study. 
Requirements for participation were providing written consent for participation, undergo 
physical examination, completing the questionnaires and having venous blood samples drawn. 
Except from fail in meeting any of these conditions there were no exclusion criterions. The 
subjects were called in the order in which they had been randomly selected. The final cohort 
consisted of 2816 subjects, 1811 from Vara and 1005 from Skövde, representing a 
participation rate of 81 % and 70 %, respectively, with respect to the number invited. 
In 2012-2014 subjects were summoned to a follow-up survey in the same order as for the 
baseline survey. Due to the complex and costly study protocol only the first 1954 individuals 
were invited. Among those 490 declined participation, 85 were deceased, 35 had moved from 
the region and 17 were unable to participate due to other reasons, leaving 1327 (68 % of the 
subjects invited to follow-up) participating in the second survey. Among those 198 had been 
diagnosed with hypertension at baseline or earlier and were therefore excluded from the 
present part of the study, leaving 1129 subjects finally included in the analysis. Fig 3.1 shows 
an overview of the Vara-Skövde cohort and study design. 
 
Data collection 
At both surveys participants were seen at least at two occasions (extra visits were conducted if 
blood pressure or fasting glucose exceeded normal) the first in the morning after a 10 h fast 
and the second about two weeks later for blood pressure measurements. The visits followed 
the same procedures at both surveys, described below, and was conducted by trained study 
nurses. 
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Blood pressure measurement. The procedure was carried out according to expert guidelines 
[13] as follows. After five minutes rest, blood pressure was measured in the right brachial 
artery, two times, one minute apart, with the subjects in a supine position with the cuff in 
heart position supported by a pillow. TricuffTM was used for automatic adjustment of cuff 
size to arm circumference and reading was done at the closest 2 mmHg. Heart rate was 
registered simultaneously with blood pressure. 
Blood pressure classification. If treatment against hypertension had been initiated during 
follow-up time hypertension was considered regardless of actual blood pressure. If else, when 
the observed blood pressure was at least 140 mmHg systolic and 90 mm Hg diastolic (one or 
both), the subject was seen again and if blood pressure still exceeded normal, a third time with 
1-2 weeks between the visits. Following this procedure three consecutive high reading was 
required for a new diagnosis of hypertension at both surveys. Blood pressure was further 
categorized according to European and American expert guidelines into optimal, normal, high 
normal blood pressure, and manifest hypertension, respectively, (Table 1.1). If systolic and 
diastolic blood pressures were falling in different categories the higher was applied. An 
unstable blood pressure category was further added, covering subjects with high readings on 
one or two visits but not on three. 
Diabetes. New diagnosis of diabetes mellitus was confirmed after two fasting plasma glucose 
values of ≥ 7.0 mmol/L, or one 2-h plasma glucose value of ≥ 11.1 mmol/L in an oral glucose 
tolerance test. [BD 83] Differentiation between type 1 and type 2 diabetes was based on 
clinical criteria, i.e. age at onset, body weight, symptoms at initial stage, tendency of ketosis, 
treatment and in some cases C-peptide. 
Body measurements. Body weight was measured with participants shoeless, wearing light 
clothing, on a calibrated scale to the nearest 0.1 kg. Body height was measured without shoes 
to the nearest cm. Waist circumference was measured between the lowest rib margin and iliac 
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crest and hip circumference at the largest circumference between waist and thighs. Waist-hip 
ratio was defined as the waist circumference divided by the hip circumference. Body mass 
index (BMI) was calculated by the body weight in kg divided by the square of the height in 
meters (kg/m2). 
Laboratory examination. Venous blood samples were drawn in the morning after an overnight 
fast (10 h minimum, patients with insulin-treated diabetes excepted, since fast was considered 
unsuitable for them). Serum cholesterol, triglycerides, blood glucose, serum insulin, c-reactive 
protein (CRP) and creatinine were analyzed according to standard procedures, previously 
described in detail [49]. Oral glucose tolerance test was performed through intake of a 75 g 
standard glucose load, with the final blood sample for glucose level analysis was drawn after 
two hours. Insulin resistance was estimated based on the Homeostasis Model Assessment of 
insulin resistance (HOMA-ir): fasting insulin × fasting blood glucose / 22.5. 
Medical history. Study nurses collected information on medical history and current 
medication according to predefined criteria from the subjects at both surveys, including 
occurrence of previous acute myocardial infarction, acute stroke and diabetes mellitus, as well 
as family history of hypertension among first-degree relatives. 
Questioners. Participants filled out validated lifestyle questioners, as well as questionnaires 
regarding psychosocial health, stress and quality of life. 
Questions, answer alternatives and variable dichotomization of the questioner derived 
variables used in this project (name of variable used in tables in italics): 
- “How physically active are you during your leisure time? The question is referred to the 
last year. 1) Sedentary leisure time: reading, watching television, stamp collecting or other 
sedentary activity; 2) Light leisure time physical activity: walking, cycling, or similar 
physical activity at least four hours per week; 3) Moderate leisure time physical activity: 
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running, swimming, tennis, aerobic, heavier gardening, or similar activity during at least 2 
hours per week; 4) Heavy training or competitive sport in running, skiing, swimming, 
football, etc., performed regularly and several times a week”. Leisure time physical 
activity (LTPA) was dichotomized into low LTPA (1+2) and active LTPA (3+4). 
- “How would you describe your current state of health in general? 1) Very good 2) Good 
3) Fairly good 4) Poor 5) Very poor”. Self-rated health was dichotomized into Good self-
rated health (1+2) and poorer self-rated health (3+4+5). 
- “Do you think your efforts are important for maintaining good health? 1) Yes I think my 
own efforts are very important 2) Yes, I think my own efforts are of some importance 3) 
No, I don’t think my own efforts are of any importance”. Self-efficacy was dichotomized 
into “I think my own efforts are of great importance” (1) and “I think my own efforts are 
of less importance” (2+3). 
- “Do you get enough sleep at night to feel rested? 1) Yes, generally 2) Not often enough 3) 
No, never or almost never”. Self-reported feeling of being rested after sleep (thoroughly 
rested after sleep) was dichotomized into “Yes, most of the time” (1) and “Not often 
enough” (2+3). 
- “Do you feel stressed in your everyday life? 1) Yes, a lot of the time 2) Yes, sometimes 3) 
No, never”. Self-reported degree of stress in everyday life (everyday stress) was 
dichotomized into “Yes” (1) and “No, seldom” (2+3). 
- Current smoking was defined as daily smoking (yes/no). 
- Alcohol consumption was assessed by questions concerning the number of days during 
the past 30 days during which the subject had consumed beer, wine and strong liquor, 
respectively, followed by the question of how many glasses, cans and/or bottles that were 
normally consumed on such days. Based on this information the quantity of alcohol in 
grams consumed per week was calculated. 
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Statistical methods 
All statistical analyses were performed using the SPSS software package for Windows, 
version 24.0. Standard methods were used for descriptive statistics. Results were expressed in 
terms of mean and standard deviation (SD) for al continuous variables except for those 
appearing to have a skew distribution, namely triglycerides, HOMA-ir, CRP and amount of 
consumed alcohol, for which median and interquartile range (P 25 - P 75) were used. All 
statistical tests were two sided, and statistical significance was assumed at p<0.05. For 
comparison between groups multiple logistic regression was used with associations expressed 
as odds ratios (OR) with 95 % confidence intervals (CI). Two different analyses were 
performed with the outcome “hypertension or no hypertension at follow-up” and progression 
or regression/stagnation with respect to blood pressure category during the follow-up time”. 
To adjust for possible contextual differences between municipalities of Vara and Skövde, and 
for differences in lifestyle between residents in the two regions, study site was included as a 
covariate in the analysis, and so was also time between baseline and follow-up visit (8-12 
years). To further account for possible confounding the following variables were introduced  
as covariates in a stepwise fashion (to avoid over adjustment): sex, age, BMI, low-density 
lipoprotein (LDL), CRP, estimated glomerular filtration rate (eGFR), weekly alcohol 
consumption, smoking status, degree of LTPA, previous CVD events, family history of 
hypertension and blood pressure category at baseline. All the variables used in the multiple 
binary logistic regression model were recorded at the baseline survey, except for information 
on family history, taken from follow-up. To investigate possible sex-differences stratification 
for sex was performed and interaction terms including sex were tested. To compare the 
impacts of the predicting variables the Wald chi-square value for each variable of statistically 
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significant contribution in the multiple logistic regression model (p<0.05 required) was 
divided by the sum of the Wald chi-square values of all the significantly contributing 
variables. These fractions were used in Figure 5.5 and 5.6. 
The relationship between OR and risk ratio (RR) is mathematically described as: 
RR=OR/(1−p0+(p0×OR)) [50], where p0 is the baseline risk (in this case probability of 
subjects of optimal BP to develop hypertension during follow-up). When p0≤0.1 OR and RR 
are usually considered approximately equal [50]. P0≤0.1 can be assumed in this case. 
 
4. Ethics 
Since this project evolves personal data obedience of The Personal Data Act 
(Personuppgiftslagen, PuL) was required as well as subjects’ informed consent. The ethical 
board at the University of Gothenburg has approved the use of the Vara-Skövde cohort for all 
parts of this project. All participants have given informed signed consent before being 
enrolled in the study. 
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5. Results 
Characteristics of the population with respect to sex, age, anthropometric and metabolic data 
and life style factors at baseline are presented in Table 5.1. Among the 1129 participating 
subjects 633 (56.1%) had optimal blood pressure, 292 (25.9%) had normal blood pressure, 
141 (12.5%) had high normal blood pressure and 63 (5.6 %) had unstable blood pressure at 
the baseline survey, see Fig 5.1. Fig 5.2 shows blood pressure category distribution at the 
follow-up survey. We observed 179 (15.9 %) incident cases of hypertension during follow-up. 
Of those with optimal blood pressure at baseline, 18 (2.8 %) converted to hypertension. 
Corresponding numbers for subjects with normal and unstable blood pressure were 58 
(19.9%) and 47 (74.6 %) respectively. Among subjects with high normal blood pressure at 
baseline, 29 (20.6 %) remained in the high normal category while 31 (22.0 %) and 11 (7.8 %) 
regressed to the normal and optimal group, respectively, 14 (9.9 %) transferred into the 
unstable group and 56 (39.7 %) progressed to hypertension, see Fig 5.3. Characteristics of the 
study population for each blood pressure category group at follow-up is presented in Table 
5.2. Age, BMI, WHR, fastening plasma glucose, HOMA-ir and CRP increased with category 
from optimal to normal, high normal and in many cases throughout unstable and are highest 
in subjects with hypertension. History of CVD and family history of hypertension is also 
observed as increasing with category. 
The mean difference in blood pressure was an increase of 5.6 mmHg (SD 11.6), systolic, and 
2.9 mmHg (SD 9.4), diastolic. 44.5 % of the subjects remained stable between baseline and 
follow-up with respect to blood pressure category while 46.1 % progressed into higher 
categories, and the rest, 9.4 %, showed decrease in category. Regression or stagnation versus 
progression within each baseline blood pressure category are shown in Fig 5.4 and indicates 
unstable blood pressure category members to be at the highest risk for progression. The 
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transitions between categories can be viewed in detail in Table 5.3. The different number of 
steps change in respect to blood pressure category taken between baseline and follow-up by 
the entire population as well as within each baseline blood pressure category is displayed in 
Table 5.4. 
Both normal, high normal and unstable baseline blood pressure were associated with an 
increased odds for development to manifest hypertension compared to optimal blood pressure, 
with odds ratios (OR (95% CI)) of 5.4 (CI 2.9-9.9), 12.5 (CI 6.3-25) and 87.5 (CI 33-231), 
respectively, independent of sex, age, municipality, time to follow up, BMI, serum levels of 
LDL and CRP, eGFR, amount alcohol consumed per week, current smoking status, degree of 
leisure time physical activity, experience of previous cardiovascular disease events and family 
history of hypertension. A trend test showed that the OR for incident hypertension per unit 
increase of baseline blood pressure category was 3.8 (CI 2.9-5.0). The progression to 
hypertension was also independently predicted by age, BMI and family history of 
hypertension with OR 1.03 (1.00-1.05), 1.12 (1.05-1.19) and 2.59 (1.59-4.23), respectively. 
Smoking did not show a significant association on the conversion to hypertension but 
presented with OR 1.53 (0.83-2.80). (See Table 5.5 and Fig 5.5.) 
Progress of blood pressure category was, when adjusting for the same variables as in the 
previous analysis, independently predicted by age, BMI and family history of hypertension 
with OR of 1.03 (1.02-1.05), 1.06 (1.02-1.10) and 1.69 (1.28-2.23) respectively. Furthermore, 
current smoking versus current non-smoking predicted category progress with OR 1.72 (1.16-
2.56). (See Table 5.6 and Fig 5.6.) 
Stratification for sex reviled no essential sex-differences, and when adjusting for age no 
significant interactions between sex and each of the other factors included in the multivariable 
analysis were found. 
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6. Discussion 
This 10 years long observational study showed that subjects of normal, high normal and 
unstable blood pressure were at a stepwise increasing risk of developing hypertension 
compared to subjects of optimal blood pressure, independent of age and other main 
cardiovascular risk factors. The conversion rate was substantial in all three baseline categories 
but more so in the high normal category and especially in the unstable. Blood pressure 
category at baseline was the by far strongest predictor of development to manifest 
hypertension, but of significant impact were also, in descending order, family history of 
hypertension, overweight and age. These findings are essentially in accordance with previous 
studies [11, 40, 51, 52]. ORs obtained in this analysis were generally higher than values 
obtained in other studies, despite equal or higher hypertension conversion rates seen in the 
other studies, and fairly comparable populations with respect to age and comorbidity. A 
plausible explanation is the fact that several of these [11, 40] have used normal blood pressure 
(BP <130/85 mmHg) as a reference, therefore naturally a higher baseline risk of hypertension 
development. In one of the studies [52], which is a new cohort within the Framingham study, 
OR figures are more similar to ours but still smaller, probably because of the fact that though 
they have used optimal category as a reference, they still saw substantially higher conversion 
rate for this category than we did in the corresponding group. Unstable blood pressure at the 
baseline survey was associated with the highest risk of development of hypertension and the 
vast majority in this category were converting. Possibilities to compare this result with 
previously obtained are limited due to the fact that the definition of unstable blood pressure is 
not generally acknowledged. The question emerging is whether the condition of a blood 
pressure shifting between normal and hypertensive values resembles another significant step 
on the road towards hypertension, as our data indicate. In a forthcoming analyze this group 
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should be more carefully studied, starting from available data, determining blood pressure 
range of these individuals. The association of ageing and overweight to the development of 
hypertension is well established [4]. Hypertension is also known to cluster within families, 
still the family history variable is not seldom left out in studies [11, 40, 52]. Our finding, that 
family history was strongly associated with development of hypertension, therefore serves as 
an important reminder of the clinical implications of theoretical heritability. 
The results concerning overall progression in blood pressure category were considered a 
secondary aim, but were nevertheless interesting. Variables showing significant impact on 
outcome were age, BMI, smoking and family history of hypertension, with age and family 
history accounting for 1/3 of the significant associations each with last 1/3 being equally 
distributed between BMI and smoking. Baseline blood pressure was notably not significantly 
associated with progress in blood pressure category, resembling a counter-intuitive contrast to 
the progression proportions displayed in Figure 5.4. We believe though that this is a less 
cogent finding and an effect of lower categories inability to lower even more, especially in the 
optimal category where category regress is not possible. Age showed a comparatively strong 
association with blood pressure category progression compared with development of 
hypertension, a possible interpretation being that age, as well known, is important for the 
initiation and progression of structural changes leading to hypertension but after reaching a 
certain increase in the level of blood pressure, possibly already at young age, you have 
entered an unstoppable train, taking no heed of chronological age. The strong association of 
smoking to blood pressure category progression constitutes an interesting finding since 
previous results concerning the effects of smoking on blood pressure differ [26]. In a cross-
sectional study on factory employees in Israel [26] smokers, despite of careful attention to 
possible confounders, were found to have in average lower blood pressure than both non-
smokers and ex-smokers. A 14 years longitudinal study conducted on Japanese workers at a 
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steel company [7] though, showed an increased risk of incident hypertension over time among 
smokers, compared to non-smokers, consistent with or results. The fact that smoking was 
significantly associated with progression in blood pressure category, made it reasonable to 
expect that it would also show significant effect on the conversion to hypertension, which was 
not the case. ORs for smoking are very similar in both analyses though, leading us to believe 
that the mentioned lack of significance could be a matter of power, owing to the fact that the 
group of individuals progressing in respect to blood pressure category is substantially larger 
than the group converting to hypertension (521 compared to 179). Reversed causation can nor 
yet be ruled out, since smoking individuals diagnosed with hypertension during follow-up 
time might have followed advice to quit smoking cessation upon diagnosis, therefore being 
underrepresented among incident hypertension cases. Previous smoking was not taken into 
account, something that should be done in future analysis of available data. 
The aim of this study was to determine the conversion rate and calculated risk for incident 
hypertension in different blood pressure categories in a relatively young Swedish population 
sample. The results are in accordance with previous studies and confirm the fact that also a 
mild blood pressure elevation, also in middle age, constitutes a serious risk factor for future 
hypertension. We also pose a new question concerning the significance of occasional 
hypertensive blood pressure readings, as our results indicate that “one time is no time”, as the 
Swedish expression goes, might not be entirely true for blood pressures. Home – or 
ambulatory blood pressure measurements is an option to consider in those cases and clinical 
follow-up is advisable. CVD-risk grading tools, such as SCORE [41], are important 
instruments for cardiovascular disease- and death-risk calculation and can serve as support in 
approaching question of treatment initiation. We believe however, that in order to make 
prevention of cardiovascular disease more effective, use of early prevention of hypertension is 
essential. Results obtained from this study can be instantly implemented into clinical practice 
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of primary care, in a cost-effective manner, through doctors including our findings in their 
choice of questions to the patients and in their risk analysis, thereby better assessing the risk 
of hypertension development and the need of lifestyle interventions in these patients. In the 
larger forthcoming picture our results can actually open up for the development of 
hypertension-risk grading tools, taking both systolic and diastolic baseline blood pressure, 
age, BMI and family history of hypertension into account, thereby presumably assessing risk 
for hypertension with greater precision. Future studies should focus on developing such tools, 
as well as more precisely evaluate the benefits and optimal design of life style interventions 
for subjects with normal, high normal or unstable blood pressure, with respect both to medical 
effects, quality of life and economic efficiency. 
Methodological considerations. Major strengths of this study is its fairly large population-
based sample, with high participation rate, including both men and women in relatively young 
age forming a suiting sample for the studying of earlier stages of hypertension development. 
Additional strengths include the strict procedures according to which blood pressures were 
measured and other diagnostic procedures were carried through, the former limiting the risks 
of overestimating of blood pressures due to randomly high values as is the risk when new 
diagnosis of hypertension is based on only one measurement. There were also very few 
exclusion criteria, and at follow-up the baseline protocol was also very closely followed. 
Limitations of this study include the well-known risk for inaccuracy regarding self-reported 
information. Furthermore the study did not take into account diet and especially not salt 
consumption, an important factor in hypertension etiology and a potential confounder. More 
information on socioeconomic aspects could also have been valuable in the analysis as well as 
an extended analysis of smoking habits taking at least previous smoking into account. Lastly, 
there were no non-participation analysis performed on subjects declining participation in 
baseline survey or dropping out for the follow-up. Despite a high participation rate such 
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analysis would have provided better control for confounding due to the possibility of certain 
features being over represented in the participating population as compared to the non-
participating population. 
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7. Conclusions 
Baseline blood pressure category has a major impact on the risk of developing hypertension. 
Subjects with high normal or unstable blood pressure should be identified in clinical practice 
and evaluated both for global cardiovascular risk and for the risk of progression to manifest 
hypertension, also accounting for family history of hypertension. Preventive strategies should 
include individualized advice on life style modification, all to avoid or postpone the 
development of hypertension, thereby reducing the risk of cardiovascular disease and 
postpone death. 
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8. Figures 
 
 
 
Figure 3.1. Overview of the Vara – Skövde cohort: study design and follow-up.  
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Figure 5.1. Distribution of blood pressure categories in the study population at baseline. 
 
 
 
Figure 5.2. Distribution of blood pressure categories in the study population at follow-up. 
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Figure 5.3. Proportion developing hypertension during follow-up time within each baseline blood 
pressure category. 
 
 
 
Figure 5.4. Regression or stagnation versus progression during follow-up time within each baseline 
blood pressure category. 
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Figure 5.5. Main determinants of hypertension conversion over 10 years (based 
on Wald chi-square values for the individual factors). 
 
 
 
Figure 5.6. Main determinants of blood pressure category progression over 10 
years (based on Wald chi-square for the individual factors). 
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9. Tables 
 
Table 5.1. Study characteristics of the population at the baseline survey.  
 
Abbreviations: BMI –  body mass index, WHR – waist hip ratio, eGFR – estimated glomerular 
filtration rate, LDL – low-density lipoprotein, HDL – high-density lipoprotein, HOMA-ir – 
homeostatic model assessment of insulin resistance, CRP –  c-reactive protein, CVD – cardiovascular 
disease, SD – standard deviation, % – percent of total. 
 
 
 
Mean SD
Age (yers) 47.1 10.8
BMI 26.2 3.8
WHR 0.9 0.1
Heart rate (beats/min) 63 8
eGFR (mL/min) 86.5 14.5
Fasting plasma glucose (mmol/L) 5.3 0.7
LDL-cholesterol (mmol/L) 3.2 0.9
HDL-cholesterol (mmol/L) 1.3 0.3
Median
Triglycerides (mmol/L) 1.05 0.77-1.45
HOMA-ir 1.14 0.77-1.73
CRP (mg/L) 1.18 0.67-2.31
Alchohol (g/week) 25.2 8.2-61.7
Number %
Sex (men) 555 49.2
Diabetes mellitus II (affected) 27 2.4
Smoking (current daily smokers) 158 14
Leisure-time physical activity (active level) 381 33.7
Self-rated health (good) 269 23.9
Self-efficacy (high) 891 78.9
Everyday stress (affirmative) 189 16.7
Thoroughly rested after sleep (affirmative) 705 62.4
Family history of hypertension (affected) 518 45.9
Experienced CVD episodes (affected) 14 1.2
N=1129 (100 %)
       
(kg/   
           )
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Table 5.2. Study characteristics for each blood pressure category-defined group at follow-up survey. 
 
Abbreviations: BMI –  body mass index, WHR – waist hip ratio, eGFR – estimated glomerular filtration rate, LDL – low-density lipoprotein, HDL – high-density lipoprotein, 
HOMA-ir – homeostatic model assessment of insulin resistance, CRP –  c-reactive protein, CVD – cardiovascular disease. SD – standard deviation, N – number, % - percent 
of total within each blood pressure category. 
.
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age (years) 47.1 0.3 42.9 0.4 46.2 0.6 50.4 0.8 52.3 1.3 54.0 0.8
27.0 0.1 25.9 0.2 27.2 0.2 27.5 0.3 26.8 0.7 28.6 0.3
WHR 0.91 <0.01 0.88 <0.01 0.92 0.01 0.93 0.01 0.94 0.01 0.94 0.01
Heart rate (beats/min) 64.6 0.3 62.7 0.4 65.0 0.6 66.6 0.7 65.4 1.3 66.2 0.7
eGFR (mL/min) 80.8 13.7 79.9 12.3 82.5 14.6 81.3 13.7 79.5 13.2 80.3 15.4
Fasting plasma glucose (mmol/L) 5.6 <0.1 5.4 <0.1 5.6 0.1 5.7 0.1 5.8 0.1 5.9 0.1
LDL-cholesterol (mmol/L) 3.5 <0.1 3.4 <0.1 3.6 0.1 3.7 0.1 3.9 0.1 3.4 0.1
HDL-cholesterol (mmol/L) 1.5 <0.1 1.5 <0.1 1.5 <0.1 1.5 <0.1 1.6 0.1 1.4 <0.1
Median Median Median Median Median Median
Triglycerides (mmol/L) 1.03 0.78-1.38 0.93 0.71-1.23 1.03 0.82-1.4 1.16 0.84-1.45 1.17 0.86-1.53 1.21 0.9-1.6
Homa-ir 1.83 1.29-2.78 1.51 1.11-2.26 1.86 1.37-2.66 2.07 1.47-3.41 1.93 1.42-3.13 2.41 1.62-3.44
CRP (mg/L) 1.31 0.68-2.59 1.04 0.3-1.94 1.22 0.67-2.63 1.6 0.85-2.99 1.37 0.72-3.01 1.95 1.06-3.31
Alchohol (g/week) 29.4 7.5-63.8 28.4 7.6-58.5 33.8 11.2-70.4 31.9 6.3-68.9 29.8 0-80.6 25.4 3.8-61.5
N % N % N % N % N % N %
Sex (men) 555 49.2 182 40.4 151 55.3 100 55.9 23 47.9 99 55.3
Diabetes mellitus II (affected) 48 4.3 7 1.6 8 2.9 6 3.4 2 4.2 25 14.0
Smoking (current daily smokers) 122 10.8 48 10.7 33 12.1 15 8.4 5 10.4 21 11.7
Leisure-time physical activity (active level) 435 38.5 208 46.2 96 35.1 59 32.9 19 39.6 53 29.6
Self-rated health (good) 838 74.2 358 79.5 207 75.8 129 72.0 35 73.0 109 60.9
Self-efficacy (high) 915 81.0 391 86.9 214 78.4 147 82.1 34 70.8 129 72.1
Everyday stress (affirmative) 129 11.4 68 15.1 35 12.8 12 6.7 1 2.1 13 7.3
Thoroughly rested after sleep (affirmative) 816 72.3 326 72.4 199 72.9 131 73.2 38 79.2 122 68.2
Family history of hypertension (affected) 518 45.9 185 41.1 121 44.3 84 46.9 24 50.0 104 58.1
Experienced CVD episodes (affected) 47 4.2 8 1.8 6 2.2 6 3.4 2 4.2 25 14.0
Blood pressure category at follow-up
High normal
N=179 (15.9%)
Unstable
N=48 (4.3%)
Hypertension
N=179 (15.9%)
All
N=1129 (100%)
Optimal
N=450 (39.9%)
Normal
N=273 (24.2%)
                                          
BMI (      
           )
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Table 5.3. Transition between categories between baseline and follow-up. 
 
Number of subjects and (row percentage). 
 
 
 
Table 5.4. Change in levels for blood pressure categories between baseline and follow-up in different baseline blood 
pressure categories. 
 
Number of subjects and (row percentage). 
Baseline category
Optimal Normal High normal Unstable Hypertensive Row total
Optimal 387 (61.1) 156 (24.6) 64 (10.1) 8 (1.3) 18 (2.8) 633 (100)
Normal 52 (17.8) 82 (28.1) 78 (26.7) 22 (7.5) 58 (19.9) 292 (100)
High normal 11 (7.8) 31 (22.0) 29 (20.6) 14 (9.9) 56 (39.7) 141 (100)
Unstable 0 (0) 4 (6.3) 8 (12.7) 4 (6.3) 47 (74.6) 63 (100)
Column total 450 (39.9) 273 (24.2) 179 (15.9) 48 (4.3) 179 (15.9) 1129 (100)
Category at follow-up
Baseline category
-3 -2 -1 0 1 2 3 4
Optimal 387 (61.1) 156 (24.6) 64 (10.1) 8 (1.3) 18 (2.8)
Normla 52 (17.8) 82 (28.1) 78 (26.7) 22 (7.5) 58 (19.9)
High normal 11 (7.8) 31 (22.0) 29 (20.6) 14 (9.9) 56 (39.7)
Unstable 0 (0) 4 (6.3) 8 (12.7) 4 (6.3) 47 (74.6)
All 0 (0) 15 (1.3) 91 (8.1) 502 (44.5) 295 (26.1) 142 (12.6) 66 (5.8) 18 (1.6)
Transition in categorical steps
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Table 5.5. Odds ratios (OR) for converting to manifest hypertension during follow-up. 
  OR 95 % CI p-value 
Sex* 1.13 0.70-1.82 0.617 
Age 1.03 1.0-1.05 0.049 
District* 10.8 0.15-772 0.274 
Time to follow up 0.49 0.11-2.18 0.347 
BMI 1.12 1.05-1.19 <0.001 
LDL 0.96 0.73-1.25 0.738 
CRP 1.01 0.97-1.06 0.601 
eGFR 1.01 0.99-1.02 0.314 
Alcohol 1.00 0.99-1.00 0.252 
Smoking* 1.53 0.83-2.80 0.173 
Leisure time physical activity* 1.15 0.70-1.89 0.588 
Undergone CVD* 5.13 0.98-26.9 0.053 
Family history of hypertension* 2.59 1.59-4.23 <0.001 
Blood pressure category at baseline*:       
Optimal 1     
Normal 5.40 2.93-9.94 <0.001 
High normal 12.5 6.28-24.8 <0.001 
Unstable 87.5 33.1-231 <0.001 
 
Multivariable analysis where each variable has been considered under adjustment for all the others. 
Extra bold type indicates significance p<0.05. 
Asterix indicates that the variable has been considered as categorical using the following as 
reference: sex - woman, district - Skövde, smoking - no, physical activity - active LTP, undergone 
CVD - no, family history of hypertension - no, blood pressure category at baseline - optimal. 
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Table 5.6. Odds ratios for progression in blood pressure category during follow-up. 
  OR 95 % CI p-value 
Sex* 1.28 0.96-1.71 0.097 
Age 1.03 1.01-1.05 <0.001 
District* 1.10 0.10-11.8 0.937 
Time to follow up 1.06 0.46-2.43 0.890 
BMI 1.05 1.02-1.10 0.006 
LDL 0.99 0.84-1.18 0.927 
CRP 1.03 0.99-1.07 0.201 
eGFR 1.01 1.00-1.02 0.121 
Alcohol 1.00 0.998-1.00 0.972 
Smoking* 1.69 1.14-2.51 0.008 
Leisure time physical activity* 1.00 0.75-1.33 0.996 
Undergone CVD* 5.54 0.66-46.3 0.114 
Family history of hypertension* 1.69 1.28-2.23 <0.001 
Blood pressure category at baseline 1.07 0.90-1.27 0.472 
 
Multivariable analysis where each variable has been considered under adjustment for all the others. 
Extra bold type indicates significance p<0.05. 
Asterix indicates that the variable has been considered as categorical using the following as 
reference: sex - woman, district - Skövde, smoking - no, physical activity - active LTP, undergone 
CVD - no, family history of hypertension - no, blood pressure category at baseline – optimal 
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